Agios second shot at sickle cell disease falls short on July 22, 2026 Agios Pharmaceuticals Anemia, Sickle Cell Decision development aspects discontinued mitapivat PK activator PYRUKYND tebapivat United States Food and Drug Administration +
Agios' Sickle Cell Trial Falls Short as Mitapivat Fails to Significantly Reduce Pain Crises on November 20, 2025 Agios Anemia, Sickle Cell Clinical Trials hemoglobin response mitapivat pain crises PYRUKYND Rise Up trial +
FDA Pushes Back Agios' Pyrukynd Thalassemia Decision to December on September 05, 2025 Agios decision delay Liver damage PDUFA PYRUKYND REMS Thalassemia United States Food and Drug Administration +